Expanding Research Scope VectorBuilder's wide adoption by over 50,000 customers across academic, biotech, pharma, and government sectors highlights significant opportunities to offer tailored gene delivery solutions and expand into emerging therapeutic areas like gene therapy and ophthalmology.

Recent Product Launches Innovative products such as the MuteFree AAV and MiniVec plasmid system demonstrate VectorBuilder's commitment to advancing gene delivery technology, creating potential upsell opportunities for clients seeking cutting-edge tools for safer and more scalable genetic medicine development.

Leading Industry Recognition Multiple awards and high-impact citations position VectorBuilder as a leader in gene therapy and CDMO innovation, providing an opportunity to leverage brand authority when engaging prospective customers in competitive bidding or collaboration discussions.

International Presence With branches across North America, Europe, China, Japan, South Korea, and Australia, VectorBuilder's global footprint enables targeted outreach and regional market penetration, especially in high-growth biotech hubs seeking reliable gene delivery partners.

Strategic Partnerships Collaborations like the Ikarovec partnership suggest opportunities to co-develop advanced gene therapies, offering a pathway to expand product offerings and establish long-term, revenue-generating alliances with biotech innovators.